Background
There have been dramatic changes in the treatment of rheumatoid arthritis (RA) in the last 20 years with the introduction of hugely effective new classes of drugs (Biologics) and with a more aggressive treatment at an early stage to limit the damaging inflammatory process of this disease. However, in the midst of all these exciting medical advances there is still a big question that has not yet been solved - which patients will respond best to which drugs? Current treatment is still a frustrating process of trial and error for the patient with potential unwanted side-effects, joint damage and worse outcomes, a reality of the waiting process.